The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Linezolid: a review of its properties, function, and use in critical care
Open accessAbstract
Linezolid can be considered as the first member of the class of oxazolidinone antibiotics. The compound is a synthetic antibiotic that inhibits bacterial protein synthesis through binding to rRNA. It also inhibits the creation of the initiation complex during protein synthesis which can reduce the length of the developed peptide chains, and decrease the rate of reaction of translation elongation. Linezolid has been approved for the treatment of infections caused by vancomycin-resistant Enterococcus faecium , hospital-acquired pneumonia caused by Staphylococcus aureus , complicated skin and skin structure infections (SSSIs), uncomplicated SSSIs caused by methicillin-susceptible S . aureus or Streptococcus pyogenes , and community-acquired pneumonia caused by Streptococcus pneumoniae . Analysis of high-resolution structures of linezolid has demonstrated that it binds a deep cleft of the 50S ribosomal subunit that is surrounded by 23S rRNA nucleotides. Mutation of 23S rRNA was shown to be a linezolid resistance mechanism. Besides, mutations in specific regions of ribosomal proteins uL3 and uL4 are increasingly associated with linezolid resistance. However, these proteins are located further away from the bound drug. The methicillin-resistant S . aureus and vancomycin-resistant enterococci are considered the most common Gram-positive bacteria found in intensive care units (ICUs), and linezolid, as an antimicrobial drug, is commonly utilized to treat infected ICU patients. The drug has favorable in vitro and in vivo activity against the mentioned organisms and is considered as a useful antibiotic to treat infections in the ICU. Keywords: linezolid, intensive care unit, MRSA, VRE, antibacterial drugs
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Wunderink, R. G., Niederman, M. S., Kollef, M. H., Shorr, A. F., Kunkel, M. J., Baruch, A., McGee, W. T., Reisman, A., & Chastre, J. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir895 · Cited by 570
Wang, Y., Lv, Y., Cai, J., Schwarz, S., Cui, L., Hu, Z., Zhang, R., Li, J., Zhao, Q., He, T., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv116 · Cited by 546
Linezolid versus Vancomycin in Treatment of Complicated Skin and Soft Tissue Infections
Weigelt, J., Itani, K., Stevens, D., Lau, W., Dryden, M., & Knirsch, C. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.6.2260-2266.2005 · Cited by 457
Birmingham, M. C., Rayner, C. R., Meagher, A. K., Flavin, S. M., Batts, D. H., & Schentag, J. J. (2003) · Clinical Infectious Diseases · doi:10.1086/345744 · Cited by 428
Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Europe
Otter, J. A., & French, G. L. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70053-0 · Cited by 398
Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity
Gillman, P. K. (2005) · British Journal of Anaesthesia · doi:10.1093/bja/aei210 · Cited by 397
Resistance to Linezolid Caused by Modifications at Its Binding Site on the Ribosome
Long, K. S., & Vester, B. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05702-11 · Cited by 375
Methicillin-Resistant Staphylococcus aureus Therapy: Past, Present, and Future
Rodvold, K. A., & McConeghy, K. W. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit614 · Cited by 358
MacGowan, A. P. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg248 · Cited by 299
ABC-F Proteins Mediate Antibiotic Resistance through Ribosomal Protection
Sharkey, L. K. R., Edwards, T. A., & O’Neill, A. J. (2016) · mBio · doi:10.1128/mbio.01975-15 · Cited by 284
Awad, S. S., Rodriguez, A. H., Chuang, Y.-C., Marjanek, Z., Pareigis, A. J., Reis, G., Scheeren, T. W. L., Sanchez, A. S., Zhou, X., Saulay, M., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu219 · Cited by 231
Linezolid: a review of safety and tolerability
Vinh, D. C., & Rubinstein, E. (2009) · Journal of Infection · doi:10.1016/s0163-4453(09)60009-8 · Cited by 213
Safety and tolerability of linezolid
French, G. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg253 · Cited by 203
Linezolid pharmacokinetics and pharmacodynamics in clinical treatment
Dryden, M. S. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr072 · Cited by 198
Falagas, M. E. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl219 · Cited by 167
Balli, E. P., Venetis, C. A., & Miyakis, S. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01289-13 · Cited by 167
The Discovery of Linezolid, the First Oxazolidinone Antibacterial Agent
Ford, C., Zurenko, G. E., & Barbachyn, M. R. (2001) · Current Drug Targets - Infectious Disorders · doi:10.2174/1568005014606099 · Cited by 161
Agyeman, A. A., & Ofori‐Asenso, R. (2016) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-016-0156-y · Cited by 151
Antibiotic dosing in critical illness
McKenzie, C. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq516 · Cited by 144
Cox, H. S., & Ford, N. P. (2012) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.11.0451 · Cited by 141
Britt, N. S., Potter, E. M., Patel, N., & Steed, M. E. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ444 · Cited by 138
Zöller, M., Maier, B., Hornuß, C., Neugebauer, C., Döbbeler, G., Nagel, D., Holdt, L. M., Bruegel, M., Weig, T. G., Grabein, B., et al. (2014) · Critical Care · doi:10.1186/cc13984 · Cited by 131
Zhang, X., Falagas, M. E., Vardakas, K. Z., Wang, R., Qin, R., Wang, J., & Liu, Y.-N. (2015) · PubMed Central · doi:10.3978/j.issn.2072-1439.2015.03.10 · Cited by 127
Kalil, A. C., Murthy, M. H., Hermsen, E. D., Neto, F. K., Sun, J., & Rupp, M. E. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181eb3b96 · Cited by 116
Cepeda, J. A., Whitehouse, T., Cooper, B., Hails, J., Jones, K., Kwaku, F., Taylor, L., Hayman, S., Shaw, S., Kibbler, C., et al. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh048 · Cited by 114
Chuang, Y., Wang, J., Lin, H., & Chang, S. (2014) · BMC Infectious Diseases · doi:10.1186/s12879-014-0687-9 · Cited by 109
Linezolid versus vancomycin for skin and soft tissue infections
Yue, J., Dong, B. R., Yang, M. J., Chen, X., Wu, T., & Liu, G. J. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008056.pub3 · Cited by 97
Whang, D. W., Miller, L. G., Partain, N. M., & McKinnell, J. A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00714-13 · Cited by 91
Linezolid-Associated Peripheral Neuropathy
Rho, J. P., Sia, I. G., Crum, B. A., Dekutoski, M. B., & Trousdale, R. T. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.7.927 · Cited by 90
Watkins, R., Lemonovich, & File, T. M. (2012) · Core evidence · doi:10.2147/ce.s33430 · Cited by 87
Chuang, Y., Lin, H.-Y., Chen, P., Lin, C.-H., Wang, J., & Chang, S. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.07.018 · Cited by 82
Crank, C. W., Scheetz, M. H., Brielmaier, B. D., Rose, W. E., Patel, G. P., Ritchie, D. J., & Segreti, J. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.09.008 · Cited by 69
Erlandson, K. M., Sun, J., Iwen, P. C., & Rupp, M. E. (2007) · Clinical Infectious Diseases · doi:10.1086/523588 · Cited by 69
Incidence and risk factors of linezolid-induced lactic acidosis
Im, J. H., Baek, J. H., Kwon, H. Y., & Lee, J. S. (2014) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2014.12.009 · Cited by 68
SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development
Poce, G., Cocozza, M., Consalvi, S., & Biava, M. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.08.066 · Cited by 66
Linezolid‐Induced Anemia and Thrombocytopenia
Waldrep, T. W., & Skiest, D. J. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.1.109.33504 · Cited by 65
Peyrani, P., Wiemken, T. L., Kelley, R. R., Zervos, M., Kett, D. H., File, T. M., Stein, G. E., Ford, K. D., Scerpella, E. G., Welch, V., et al. (2014) · Critical Care · doi:10.1186/cc13914 · Cited by 54
Structural Basis for Linezolid Binding Site Rearrangement in the Staphylococcus aureus Ribosome
Belousoff, M. J., Eyal, Z., Radjainia, M., Ahmed, T. U., Bamert, R. S., Matzov, D., Bashan, A., Zimmerman, E., Mishra, S., Cameron, D. R., et al. (2017) · mBio · doi:10.1128/mbio.00395-17 · Cited by 54
Wang, Y., Zou, Y., Xie, J., Wang, T., Zheng, X., He, H., Dong, W., Xing, J., & Dong, Y. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1775-x · Cited by 50
Faella, F. S., Pagliano, P., Fusco, U., Attanasio, V., & Conte, M. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01352.x · Cited by 45
Zhao, M., Liang, L., Ji, L., Chen, D., Zhang, Y., Zhu, Y., & Patel, K. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.06.010 · Cited by 44
Jiang, H., Tang, R., & Wang, J. (2013) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-013-1867-z · Cited by 42
McKinnell, J. A., & Arias, C. A. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ449 · Cited by 35
Fu, J., Ye, X., Cha, C., & Chen, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058240 · Cited by 33
Collins, C. D., & Schwemm, A. K. (2015) · Value in Health · doi:10.1016/j.jval.2015.04.007 · Cited by 26
Neuropathie optique toxique grave liée au linézolide
Xerri, O., Lemaire, B., Nasser, G., Rousseau-Huvey, B., Labétoulle, M., & Rousseau, A. (2015) · Journal Français d Ophtalmologie · doi:10.1016/j.jfo.2014.05.020 · Cited by 10
von Dach, E., Morel, C. M., Murthy, A. K., Pagani, L., Macedo-Viñas, M., Olearo, F., & Harbarth, S. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.02.011 · Cited by 10
Farhadi, T. (2017) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-017-9627-z · Cited by 10
Self-citationLinezolid-Associated Serotonin Syndrome
Frykberg, R. G., Gordon, S., Tierney, E., & Banks, J. (2015) · Journal of the American Podiatric Medical Association · doi:10.7547/0003-0538-105.3.244 · Cited by 7
Cited by
Prevalence and Therapies of Antibiotic-Resistance in Staphylococcus aureus
Guo, Y., Song, G., Sun, M., Wang, J., & Wang, Y. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00107 · Cited by 870
Metadata
- Authors
- Hashemian, S. M., Farhadi, T., & Ganjparvar, M.
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2018-06
- Volume
- Volume 12
- Pages
- 1759-1767
- ISSN
- 1177-8881 (ISSN-L)
- OpenAlex
- W2808520288
- Cited by
- 459
- References
- 50
- FWCI
- 12.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.